Raiffeisen Bank International AG Has $6.12 Million Stock Position in Becton, Dickinson and Company $BDX

Raiffeisen Bank International AG cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 57.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,232 shares of the medical instruments supplier’s stock after selling 44,234 shares during the quarter. Raiffeisen Bank International AG’s holdings in Becton, Dickinson and Company were worth $6,115,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 1,354 shares during the period. United Bank grew its position in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after buying an additional 993 shares in the last quarter. Chicago Partners Investment Group LLC increased its stake in Becton, Dickinson and Company by 15.3% during the second quarter. Chicago Partners Investment Group LLC now owns 1,807 shares of the medical instruments supplier’s stock valued at $330,000 after acquiring an additional 240 shares during the period. Finally, Brookstone Capital Management raised its holdings in Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brookstone Capital Management now owns 19,500 shares of the medical instruments supplier’s stock valued at $3,359,000 after acquiring an additional 1,650 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.6%

Shares of Becton, Dickinson and Company stock opened at $185.43 on Friday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $185.50. The stock has a market capitalization of $52.80 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 13.23 and a beta of 0.25. The company has a 50-day simple moving average of $197.33 and a 200 day simple moving average of $192.24. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the prior year, the firm earned $3.43 earnings per share. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,416 shares of company stock worth $675,557. Insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a research report on Tuesday, February 10th. Citigroup lowered their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. TD Cowen raised their price objective on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Barclays initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price target for the company. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.